Nektar Therapeutics (NKTR)
74.28
+0.59
(+0.80%)
USD |
NASDAQ |
Aug 25, 13:40
Nektar Therapeutics Total Liabilities (Quarterly) : 192.01M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 192.01M |
| March 31, 2026 | 187.06M |
| December 31, 2025 | 190.57M |
| September 30, 2025 | 216.26M |
| June 30, 2025 | 231.74M |
| March 31, 2025 | 242.50M |
| December 31, 2024 | 243.11M |
| September 30, 2024 | 259.08M |
| June 30, 2024 | 263.65M |
| March 31, 2024 | 269.31M |
| December 31, 2023 | 267.05M |
| September 30, 2023 | 282.88M |
| June 30, 2023 | 297.32M |
| March 31, 2023 | 320.88M |
| December 31, 2022 | 343.96M |
| September 30, 2022 | 368.78M |
| June 30, 2022 | 403.26M |
| March 31, 2022 | 416.23M |
| December 31, 2021 | 437.68M |
| September 30, 2021 | 475.70M |
| June 30, 2021 | 466.38M |
| March 31, 2021 | 462.06M |
| December 31, 2020 | 461.47M |
| September 30, 2020 | 337.68M |
| June 30, 2020 | 338.64M |
| Date | Value |
|---|---|
| March 31, 2020 | 591.51M |
| December 31, 2019 | 571.96M |
| September 30, 2019 | 599.58M |
| June 30, 2019 | 542.50M |
| March 31, 2019 | 532.97M |
| December 31, 2018 | 432.60M |
| September 30, 2018 | 458.98M |
| June 30, 2018 | 452.67M |
| March 31, 2018 | 438.51M |
| December 31, 2017 | 421.04M |
| September 30, 2017 | 497.89M |
| June 30, 2017 | 472.47M |
| March 31, 2017 | 483.74M |
| December 31, 2016 | 480.75M |
| September 30, 2016 | 492.95M |
| June 30, 2016 | 502.35M |
| March 31, 2016 | 492.15M |
| December 31, 2015 | 495.63M |
| September 30, 2015 | 410.19M |
| June 30, 2015 | 421.57M |
| March 31, 2015 | 421.91M |
| December 31, 2014 | 405.29M |
| September 30, 2014 | 429.68M |
| June 30, 2014 | 513.50M |
| March 31, 2014 | 496.82M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Elite Pharmaceuticals, Inc. | 34.84M |
| Daré Bioscience, Inc. | 22.93M |
| Aclaris Therapeutics, Inc. | 55.11M |
| Eton Pharmaceuticals, Inc. | 69.22M |
| Journey Medical Corp. | 66.24M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.095B |
| Shareholders Equity (Quarterly) | 903.12M |
| Debt to Equity Ratio | 0.1505 |
| Current Ratio | 10.42 |
| Net Debt Paydown Yield | 0.43% |